Fig. 2. The effects of calmidazoluim (CMZ) on polycystic kidney disease 2-like-1 (PKD2L1) current under 16 nM and 100 nM intracellular free calcium concentrations. (A) A full current trace of PKD2L1 (left) activated by 1 μM of CMZ under 16 nM free Ca2+ and the current (I)–voltage (V) relationship of PKD2L1 (right) at the basal current amplitude (black) and at the application of 1 μM of CMZ (blue). (B) A full current trace of PKD2L1 (left) activated by 1 μM of CMZ under 100 nM free Ca2+ and the I–V relationship of PKD2L1 (right) at the basal current amplitude (black) and at the application of 1 μM of CMZ (blue). (C) A summarized current amplitude of PKD2L1 induced by CMZ under 16 nM and 100 nM free Ca2+ (n = 17–32). ***p < 0.001.
© Korean J Physiol Pharmacol
